Point72 Europe London LLP Has $852,000 Position in Structure Therapeutics Inc. (NASDAQ:GPCR)

Point72 Europe London LLP reduced its position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR) by 29.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 31,420 shares of the company’s stock after selling 13,413 shares during the period. Point72 Europe London LLP’s holdings in Structure Therapeutics were worth $852,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also bought and sold shares of GPCR. ANTIPODES PARTNERS Ltd lifted its position in Structure Therapeutics by 115.0% during the fourth quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company’s stock worth $28,000 after purchasing an additional 553 shares during the period. FNY Investment Advisers LLC acquired a new position in shares of Structure Therapeutics during the fourth quarter worth $40,000. Virtus ETF Advisers LLC lifted its stake in shares of Structure Therapeutics by 25.5% in the fourth quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company’s stock worth $61,000 after acquiring an additional 455 shares during the period. Assetmark Inc. lifted its holdings in Structure Therapeutics by 72.3% in the fourth quarter. Assetmark Inc. now owns 2,271 shares of the company’s stock valued at $62,000 after buying an additional 953 shares during the period. Finally, Tower Research Capital LLC TRC boosted its position in shares of Structure Therapeutics by 673.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,076 shares of the company’s stock valued at $111,000 after purchasing an additional 3,549 shares in the last quarter. 91.78% of the stock is owned by institutional investors.

Structure Therapeutics Price Performance

Shares of GPCR opened at $24.43 on Friday. The firm’s 50 day simple moving average is $21.09 and its 200 day simple moving average is $26.64. The company has a market capitalization of $1.40 billion, a P/E ratio of -33.01 and a beta of -1.69. Structure Therapeutics Inc. has a 1-year low of $13.22 and a 1-year high of $62.74.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.03). On average, equities analysts anticipate that Structure Therapeutics Inc. will post -0.82 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Citigroup assumed coverage on Structure Therapeutics in a research note on Friday, May 2nd. They issued a “buy” rating and a $60.00 price objective for the company. William Blair began coverage on shares of Structure Therapeutics in a research note on Friday, February 28th. They issued an “outperform” rating on the stock. Finally, HC Wainwright lowered their price objective on Structure Therapeutics from $80.00 to $75.00 and set a “buy” rating on the stock in a research note on Monday. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $78.00.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.